Physician profile
Patrick Johnson
NPI 1922307818
$2,204.37
in general payments reported to CMS, 2019-2025
24 companies · $288 in 2025
The $288 reported for 2025 was more than what 75% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $366 · 2021: $281 · 2022: $155 · 2023: $282 · 2024: $524 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $316.46 | 2023-2025 | Cabenuva, Apretude |
| Lilly USA, LLC | $274.04 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $244.81 | 2020-2025 | |
| Pfizer INC. | $231.00 | 2019-2025 | |
| Novo Nordisk INC | $191.48 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.92 | 2019-2022 | |
| Medtronic USA, INC. | $144.13 | 2019 | |
| Gilead Sciences, INC. | $105.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $81.37 | 2021-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Amgen INC. | $71.41 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $54.57 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Organon LLC | $43.51 | 2021-2023 | Nexplanon |
| Glaxosmithkline, LLC. | $37.75 | 2019-2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $32.08 | 2020-2021 | |
| Corium, LLC | $28.17 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.77 | 2023 | Freestyle Libre |
| Sanofi Pasteur INC. | $21.57 | 2023 | |
| Janssen Pharmaceuticals, INC | $20.96 | 2022 | |
| Cranial Technologies, INC | $20.57 | 2024 | Doc Band |
| Alkermes, INC. | $20.45 | 2024 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $19.03 | 2025 | Abilify Maintena |
| Astrazeneca Pharmaceuticals Lp | $16.98 | 2024 | Breztri |
| Dexcom, INC. | $15.15 | 2021 | |
| Phadia US INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.